SkyAI, Inc. announced a cash tender offer to buy up to 95% of its eligible shares and warrants for about $201.3 million, funded from its $223.8 million cash reserves. The offer price is $3 per share and nearly $3 per warrant, slightly reduced by exercise price. This move follows the company's plan to consolidate ownership while remaining listed on Nasdaq and developing a financial platform integrating Solana stablecoins with AI. The tender offer ends on October 30, subject to minimum tender conditions and possible extension or early termination.
SkyAI's $201 million tender offer is the subject here, provided as context for readers. For those tracking major cryptocurrencies on Pluang, 41 out of 50 rose today. Notable moves include BCH at Rp5.011.670 with a 3.75% increase and a 77% sell order activity, XTZ at Rp5.463 up 3.51% with 84% buy orders, and GRT at Rp432 rising 3.46% with 90% sell orders. Data as of Oct 19, 2026 23:31 WIB.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
